Acute Intermittent Porphyria Market is driven by Advancements in Genetic Therapeutics
The Acute Intermittent Porphyria Market encompasses therapies designed to manage the rare genetic disorder characterized by buildup of porphyrin precursors, leading to severe abdominal pain, neurological complications, and life-threatening attacks. Marketed products include intravenous hemin formulations that offer rapid symptom relief during acute episodes, and innovative RNA interference...
0 Comments 0 Shares 23 Views 0 Reviews